Pancreatic Cancer Screening Study (CAPS5)

About the Study

CAP5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer who are undergoing screening with endospic (EUS,) or . The goal is to study biomarkers derived from images and tissue samples (ex. blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.

What the Study Involves

Study participation involves:

answering online questionnaires.
donating 4 tubes of blood- for research only.
(at some sites) collecting free standing fluid in the duodenal area where the pancreas drains fluid, aspirated by scope during EUS procedures- for research only.
(at some sites and optional) collect pancreas juice via the endoscope. The pancreas is stimulated by a dose of Secretin, a synthetic pancreas hormone, injected I.V during the EUS procedure-for research only.
data from the participants medical record related to their pancreas screening and care.
optional: potential early detection blood test, pairing annual CA19-9 with the participants FUT2/FUT3 gene test to individualize the CA19-9 result. Results will be shared with the participant.

NOTE: The CAPS 5 study does not provide payment for participation and all screening tests will be submitted to the patients insurance for payment. These screening test/procedures are standard care for pancreas cancer screening for high risk individuals. For research participants, data will be collected from all screening tests/ reports for various CAPS 5 projects, but their pancreas screening will not be altered by their study participation.

Connecticut

City: New Haven RECRUITING
Facility: Yale University
Contact Info:
[email protected] 203-785-7019
James Farrell, MD

Massachusetts

City: Boston RECRUITING
Facility: Dana Farber Cancer Center, Harvard University
Contact Info:
[email protected] 617-632-4788
[email protected]
Sapna Syngal, MD
Matthew Yurgelun, MD

Maryland

City: Baltimore RECRUITING
Facility: Johns Hopkins Hospital
Contact Info:
[email protected] 410-502-2893
Michael Goggins, MD
Marcia I Canto, MD

Michigan

City: Ann Arbor RECRUITING
Facility: University of Michigan
Contact Info:
[email protected] 734-998-1274
Elena Stoffel, MD

New York

City: New York RECRUITING
Facility: Columbia University Medical Center
Contact Info:
[email protected]
Fay Kastrinos, MD

Ohio

City: Cleveland RECRUITING
Facility: Case Comprehensive Cancer Center, Case Western Medical Reserve
Contact Info:
[email protected] 216-844-7314
[email protected] 216-844-3853
Amitabh Chak, MD

Pennsylvania

City: Philadelphia RECRUITING
Facility: University of Pennsylvania
Contact Info:
[email protected] 215-360-0905
Bryson Katona, MD

City: Pittsburgh RECRUITING
Facility: University of Pittsburgh
Contact Info:
[email protected]
[email protected]
Randall Brand, MD

This Study is Open To:

This study is open to people at high risk for pancreatic cancer due to any of the following:

in the following genes: , , , FAMMM, , (, , , , ), hereditary pancreatitis (PRSS1/2, or CTRC), (Peutz-Jeghers)
With two or more close relatives, on one side of their family tree, diagnosed with pancreas cancer
Endoscopic evaluation of pancreas scheduled

*contact your doctors or the study coordinators for a complete list of inclusion criteria.

This Study is Not Open To:

This study is not open to people who:

are unable to have an endoscopy
are pregnant